| Journal | Addiction (Abingdon, England) |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
To situate Jordan within evolving Middle East and North Africa (MENA) substance-use dynamics and summarise national patterns of substance use, related harms, and policy responses, with attention to transit-to-consumption transitions, surveillance limitations, and vulnerable populations. Structured regional synthesis of government reports, peer-reviewed literature, and data from the Ministry of Health, the Anti-Narcotics Department, and international agencies. The review integrated national statistics (2019-2025) with findings from population, student, and clinical studies to outline prevalence, treatment, and regulatory contexts. Across MENA, conflict, displacement, demographic pressure, and shifting trafficking routes have coincided with expanding stimulant and pharmaceutical markets. In Jordan, a comparatively stable setting with a large youth population, available estimates suggest national substance use disorder [SUD] prevalence of ~0.9-1.7%, but substantially higher levels among s
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
